# Poster Session II - A197 LONG-TERM DUPILUMAB MAINTAINS HISTOLOGIC AND ENDOSCOPIC IMPROVEMENTS IN CHILDREN WITH EOSINOPHILIC ESOPHAGITIS (EOE): 100-WEEK DATA FROM THE OPEN-LABEL EXTENSION (OLE) OF THE EOE KIDS STUDY

## TL;DR

Dupilumab treatment for children with EoE showed lasting improvements in tissue and endoscopic results over 100 weeks with a consistent safety profile.

## Contribution

This study provides 100-week data showing sustained efficacy and safety of dupilumab in pediatric EoE patients.

## Key findings

- 68.2% of patients maintained ≤6 eosinophils/high-power field at 100 weeks.
- EoE-Histologic and Endoscopic scores showed consistent improvement from baseline.
- Mild-to-moderate adverse events were reported in 86.9% of patients during the extension phase.

## Abstract

In EoE KIDS (NCT04394351), dupilumab significantly improved histologic and endoscopic outcomes vs placebo at Week (W)16 (Part A) in patients with EoE aged 1–11 years, with benefits maintained up to W52 (Part B).

We assessed the efficacy and safety of long-term dupilumab in the EoE KIDS OLE (Part C).

Patients completing W52 of Part B could enter Part C where they received the weight-tiered, open-label dupilumab regimen subsequently approved by the FDA (similar to the Part A/B higher-exposure regimen). Efficacy data, which included patients who received placebo or dupilumab higher-exposure during Parts A and B, are reported to the last prespecified assessment at W100; safety data included all patients.

102, 98, and 61 patients enrolled in Parts A, B, and C, respectively. At W52, 69.7% (23/33) of patients who received dupilumab achieved ≤6 eosinophils/high-power field (eos/hpf) and this was maintained at W100 (68.2% [15/22]) in Part C. Similar results were reported for <15 eos/hpf (81.8% [27/33] and 90.9% [20/22] at W52 and W100, respectively). Mean changes (95% confidence interval) from Part A baseline at W52 and W100 were similar for EoE-Histologic Scoring System grade/stage scores (–0.87 [–1.01, –0.73] and –0.85 [–1.04, –0.65]/–0.83 [–0.96, –0.71] and –0.87 [–1.04, –0.70]) and EoE-Endoscopic Reference Score (–4.60 [–5.71, –3.49] and –5.44 [–6.83, –4.05]) (Figure). Mild-to-moderate adverse events (AEs) were reported in 86.9% (53/61) of patients during Part C; injection-site reaction was the most common treatment-related AE. Serious AEs were reported in 4.9% (3/61) of patients, with none deemed related to dupilumab.

Dupilumab maintained histologic and endoscopic efficacy in pediatric patients with EoE up to W100 and demonstrated a consistent safety profile.

Sanofi and Regeneron Pharmaceuticals Inc.